BCL-2 inhibitor and conventional chemotherapy combinations for acute myeloid leukemia: shifting from the unfit to the fit patient with AML

BCL-2 inhibitor and conventional chemotherapy combinations for acute myeloid leukemia: shifting from the unfit to the fit patient with AML

Bibliographic Details
Main Authors:	Ossenkoppele, G, Vyas, P
Format:	Journal article
Language:	English
Published:	American Society of Clinical Oncology 2020

Similar Items

Azacitidine prolongs overall survival in older patients with Acute Myeloid Leukemia (AML) with poor prognostic karyotypes
by: Doehner, H, et al.
Published: (2017)

Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR)
by: Doehner, H, et al.
Published: (2016)

Molecular responses during chemotherapy in acute myeloid leukemias in predicting poor-response to standard chemotherapy.
by: Abdullah, Maha, et al.
Published: (2009)

Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics
by: Fernandez-Mercado, M, et al.
Published: (2012)

An overview of targeted therapies in acute myeloid leukemia
by: Turkalj, S, et al.
Published: (2023)

The graft-versus-leukemia effect in AML
by: Sweeney, C, et al.
Published: (2019)

Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia
by: Hashimoto, M, et al.
Published: (2021)

Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
by: DiNardo, C, et al.
Published: (2019)

Assessment of minimal residual disease in acute myeloid leukemia.
by: Grimwade, D, et al.
Published: (2010)

Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).
by: Goodyear, O, et al.
Published: (2012)

AML-399 A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia (AML)
by: Vyas, P, et al.
Published: (2022)

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
by: Vyas, P, et al.
Published: (2015)

Clonal heterogeneity of acute Myeloid Leukemia treated with the IDH2 inhibitor Enasidenib
by: Vyas, P, et al.
Published: (2018)

Transformation of myelodysplastic syndrome (MDS) to acute myeloid leukaemia (AML)
by: Goh, Chermaine Yu Zhen
Published: (2021)

Myeloid pre-leukemia and leukemia of Down syndrome
by: Cruz Hernandez, D, et al.
Published: (2020)

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
by: DiNardo, CD, et al.
Published: (2020)

Autophagy in hematopoiesis and acute myeloid leukemia
by: Watson, A
Published: (2014)

AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results
by: Daver, N, et al.
Published: (2022)

Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia
by: Quek, L, et al.
Published: (2017)

Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy
by: Radujkovic, A, et al.
Published: (2016)

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
by: Döhner, H, et al.
Published: (2018)

New directions for emerging therapies in acute myeloid leukemia: the next chapter
by: Daver, N, et al.
Published: (2020)

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.
by: Mussai, F, et al.
Published: (2013)

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
by: Grimwade, D, et al.
Published: (2001)

Targeting MTHFD2 in acute myeloid leukemia
by: Pikman, Yana, et al.
Published: (2017)

Modeling CEBPA Mutant Acute Myeloid Leukemias
by: Nerlov, C
Published: (2013)

AMPLIFICATION OF MITOCHONDRIAL-DNA IN ACUTE MYELOID-LEUKEMIA
by: Boultwood, J, et al.
Published: (1994)

Clonal haematopoiesis and risk of acute myeloid leukemia
by: Young, A, et al.
Published: (2019)

Targeting MTHFD2 in acute myeloid leukemia
by: Pikman, Yana, et al.
Published: (2022)

Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)
by: Dinardo, CD, et al.
Published: (2022)

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia
by: Kinstrie, R, et al.
Published: (2016)

Normal hematopoietic progenitor subsets have distinct reactive oxygen species, BCL2 and cell-cycle profiles that are decoupled from maturation in acute myeloid leukemia
by: Khan, N, et al.
Published: (2016)

Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome.
by: Robinson, H, et al.
Published: (2003)

ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia
by: Al-Obaidi, M, et al.
Published: (2002)

Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)
by: DiNardo, CD, et al.
Published: (2021)

Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia.
by: Watson, A, et al.
Published: (2011)

Cytogenetic profile of acute myeloid leukaemia (AML) patients in Singapore General Hospital (SGH)
by: Ho, Charmaine Jia Yi
Published: (2024)

Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
by: Richards, S
Published: (1997)

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
by: Quek, L, et al.
Published: (2016)

A phase 3 study of Enasidenib (ENA) versus conventional care regimens (CCR) in older patients with late-stage mutant-IDH2 (MIDH2) relapsed/refractory acute myeloid leukemia (R/R AML)
by: Papayannidis, C, et al.
Published: (2021)